A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

University of Melbourne

Status: Unknown

Conditions: Coronary Artery Disease; Myocardial Infarction

Treatments: Drug: Abciximab

Study type: Interventional

Funder types: Other

Identifiers

NCT02105870

SVH 001

Details and patient eligibility

About

Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients suffering an acute myocardial infarction.

The investigators hypothesise that treatment with intracoronary abciximab, a potent anti platelet agent, at the time of coronary stent insertion, will improve microvascular function.

Full description

The index of microcirculatory resistance (IMR), an invasive measure of coronary microvascular function, correlates with clinical outcomes in patients with stable angina and ST elevation myocardial infarction. The glycoprotein IIb/IIIa receptor inhibitor, abciximab, improves coronary microvascular function and reduces major cardiac adverse events in patients with acute coronary syndromes. This study will investigate whether an intracoronary bolus of abciximab in patients with non-ST elevation myocardial infarction decreases IMR and improves microvascular function.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with acute coronary syndromes

Exclusion criteria

• Patient with untreated malignancy, disseminated malignancy, active inflammatory diseases, active infectious diseases patients unable to give informed consent Patients with STEMI

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

Intracoronary abciximab (Reopro)

Experimental group

Description:

Intracoronary abciximab (Reopro)

Treatment:

Drug: Abciximab

Control group

Placebo Comparator group

Description:

Intracoronary Reopro